中华结核和呼吸杂志
中華結覈和呼吸雜誌
중화결핵화호흡잡지
Chinese Journal of Tuberculosis and Respiratory Diseases
2011年
6期
409-412
,共4页
于玲玲%胡必杰%黄声雷%周昭彦%陶黎黎
于玲玲%鬍必傑%黃聲雷%週昭彥%陶黎黎
우령령%호필걸%황성뢰%주소언%도려려
微生物敏感性试验%抗菌药%嗜肺军团菌
微生物敏感性試驗%抗菌藥%嗜肺軍糰菌
미생물민감성시험%항균약%기폐군단균
Microbial sensitivity tests%Anti-bacterial agents%Legionella pneumophila
目的 评估大环内酯类和氟喹诺酮类药物对巨噬细胞内嗜肺军团菌的作用.方法 采用琼脂稀释法测量大环内酯类和氟喹诺酮类药物对20株嗜肺军团菌血清1型(L.pneumophila serogroup 1,Lp-1)的MIC值.加入佛波酯诱导人类单核细胞系THP-1分化成巨噬细胞样细胞.将Lp-1与分化的THP-1细胞共培养,细胞吞噬细菌后,加入红霉素、阿奇霉素、左氧氟沙星及莫西沙星4种抗菌药物,在1×MIC、4×MIC、8×MIC浓度时培养24 h,平板计数法双份计数细胞内存活的军团菌数.结果 以细菌抑制率表示,不同抗菌药物作用的差别采用Mann-Whitney U检验分析.结果 4种抗菌药物在1×MIC、4×MIC、8×MIC浓度时作用24 h后的细菌抑制率分别为:红霉素:(50.18±27.29)%、(79.48±20.08)%及(91.46±8.70)%;阿奇霉素:(66.77±26.18)%、(91.73±8.72)%及 (97.10±3.37)%;左氧氟沙星:(99.84±0.25)%、(99.99±0.02)%及 (99.99±0.01)%;莫西沙星:(99.90±0.10)%、(99.99±0.03)%及(99.99±0.03)%.氟喹诺酮类药物在1×MIC、4×MIC、8×MIC时对细胞内Lp-1的抑制率高于大环内酯类药物(u值分别为1.0、2.0和5.0,均P＜0.05),左氧氟沙星和莫西沙星在上述3个浓度时对Lp-1的抑制率差异无统计学意义(u值分别为190、183和217,均P＞0.05),阿奇霉素对细胞内Lp-1的抑制率高于红霉素(u值分别为132、125和128,均P＜0.05).结论 氟喹诺酮类药物细胞内抗军团菌的作用优于大环内酯类药物,左氧氟沙星和莫西沙星细胞内抗军团菌的作用相似,阿奇霉素细胞内抗军团菌的作用优于红霉素.
目的 評估大環內酯類和氟喹諾酮類藥物對巨噬細胞內嗜肺軍糰菌的作用.方法 採用瓊脂稀釋法測量大環內酯類和氟喹諾酮類藥物對20株嗜肺軍糰菌血清1型(L.pneumophila serogroup 1,Lp-1)的MIC值.加入彿波酯誘導人類單覈細胞繫THP-1分化成巨噬細胞樣細胞.將Lp-1與分化的THP-1細胞共培養,細胞吞噬細菌後,加入紅黴素、阿奇黴素、左氧氟沙星及莫西沙星4種抗菌藥物,在1×MIC、4×MIC、8×MIC濃度時培養24 h,平闆計數法雙份計數細胞內存活的軍糰菌數.結果 以細菌抑製率錶示,不同抗菌藥物作用的差彆採用Mann-Whitney U檢驗分析.結果 4種抗菌藥物在1×MIC、4×MIC、8×MIC濃度時作用24 h後的細菌抑製率分彆為:紅黴素:(50.18±27.29)%、(79.48±20.08)%及(91.46±8.70)%;阿奇黴素:(66.77±26.18)%、(91.73±8.72)%及 (97.10±3.37)%;左氧氟沙星:(99.84±0.25)%、(99.99±0.02)%及 (99.99±0.01)%;莫西沙星:(99.90±0.10)%、(99.99±0.03)%及(99.99±0.03)%.氟喹諾酮類藥物在1×MIC、4×MIC、8×MIC時對細胞內Lp-1的抑製率高于大環內酯類藥物(u值分彆為1.0、2.0和5.0,均P＜0.05),左氧氟沙星和莫西沙星在上述3箇濃度時對Lp-1的抑製率差異無統計學意義(u值分彆為190、183和217,均P＞0.05),阿奇黴素對細胞內Lp-1的抑製率高于紅黴素(u值分彆為132、125和128,均P＜0.05).結論 氟喹諾酮類藥物細胞內抗軍糰菌的作用優于大環內酯類藥物,左氧氟沙星和莫西沙星細胞內抗軍糰菌的作用相似,阿奇黴素細胞內抗軍糰菌的作用優于紅黴素.
목적 평고대배내지류화불규낙동류약물대거서세포내기폐군단균적작용.방법 채용경지희석법측량대배내지류화불규낙동류약물대20주기폐군단균혈청1형(L.pneumophila serogroup 1,Lp-1)적MIC치.가입불파지유도인류단핵세포계THP-1분화성거서세포양세포.장Lp-1여분화적THP-1세포공배양,세포탄서세균후,가입홍매소、아기매소、좌양불사성급막서사성4충항균약물,재1×MIC、4×MIC、8×MIC농도시배양24 h,평판계수법쌍빈계수세포내존활적군단균수.결과 이세균억제솔표시,불동항균약물작용적차별채용Mann-Whitney U검험분석.결과 4충항균약물재1×MIC、4×MIC、8×MIC농도시작용24 h후적세균억제솔분별위:홍매소:(50.18±27.29)%、(79.48±20.08)%급(91.46±8.70)%;아기매소:(66.77±26.18)%、(91.73±8.72)%급 (97.10±3.37)%;좌양불사성:(99.84±0.25)%、(99.99±0.02)%급 (99.99±0.01)%;막서사성:(99.90±0.10)%、(99.99±0.03)%급(99.99±0.03)%.불규낙동류약물재1×MIC、4×MIC、8×MIC시대세포내Lp-1적억제솔고우대배내지류약물(u치분별위1.0、2.0화5.0,균P＜0.05),좌양불사성화막서사성재상술3개농도시대Lp-1적억제솔차이무통계학의의(u치분별위190、183화217,균P＞0.05),아기매소대세포내Lp-1적억제솔고우홍매소(u치분별위132、125화128,균P＜0.05).결론 불규낙동류약물세포내항군단균적작용우우대배내지류약물,좌양불사성화막서사성세포내항군단균적작용상사,아기매소세포내항군단균적작용우우홍매소.
Objective To evaluate the activity of macrolides and fluoroquinolones against Legionella pneumophila by intracellular susceptibility testing. Methods Minimum inhibitory concentration(MIC) was determined by standard agar dilution test according to the CLSI. For intracellular assays, legionella pneumonia was used to infect human monocytic cell line THP-1. Erythromycin, azithromycin, levofloxacin and moxifloxacin at 1×MIC, 4×MIC, 8×MIC were added following phagocytosis. Number of viable bacteria was enumerated at 24 h on BCYE (buffered charcoal yeast extract) agar in duplicates using standard plate count method. The result was expressed as percentage inhibition. Mann-Whitney U test was used to determine the significant differences in mean percentage inhibition between agents. Results Percentage inhibition at 24 h were as follows: Erythromycin 1×MIC (50.18±27.29)%, 4×MIC (79.48±20.08)%, 8×MIC (91.46±8.70)%; Azithromycin 1×MIC (66.77±26.18)%, 4×MIC (91.73±8.72)%, 8×MIC (97.10±3.37)%; Levofloxacin 1×MIC (99.84±0.25)%, 4×MIC (99.99±0.02)%, 8×MIC (99.99±0.01)%; Moxifloxacin 1×MIC (99.90±0.10)%, 4×MIC (99.99±0.03)%, 8×MIC (99.99±0.03)%. The fluoroquinolones showed greater inhibitory activity than macrolides against legionella pneumophila(u=1.0,2.0,5.0,P＜0.05). Levofloxacin and moxifloxacin had the same intracellular activity against legionella pneumophila (u=190, 183, 217,P＞0.05). Azithromycin was more effective than erythromycin in inhibiting intracellular legionella pneumophila (u=132,125,128,P＜0.05). Conclusions The fluoroquinolones were more active than macrolides against legionella pneumophila. The intracellular activity of levofloxacin against legionella pneumophila appeared to be similar to moxifloxacin. Azithromycin was demonstrated to have superior activity against legionella pneumophila compared with erythromycin.
